BDNF and spinocerebellar ataxia type 1: Additionally, pharmacological (intraventricular) BDNF delivery had a therapeutic benefit for motor deficits and PC pathology at the early [8] and post-symptomatic [7,9] stages of the disease in different mouse models of SCA1.